Elacestrant (Orserdu; RAD1901; CAS 1349860-02-1): NIOSH HD Category 1 SEVENTY-SECOND Mechanism Class [FIRST ORAL SERD (SELECTIVE ESTROGEN RECEPTOR DEGRADER) EVER FDA APPROVED (NDA 216863; January 27, 2023; ER+/HER2− mBC ESR1 Mutation; Helix-12 AF-2 Disruption; NCoR/SMRT Corepressor Recruitment; Ubiquitin-Proteasome ESR1 Protein Degradation; First Oral Pill SERD vs Fulvestrant IM Injection [Faslodex; First SERD; Apr 2002; No Oral Bioavailability]; ESR1 D538G Helix-12 Stabilized Constitutive Active + Y537S/N/C Helix-12 Fully Constitutive; EMERALD All-Comers PFS HR 0.55 (p=0.002); ESR1-Mutant PFS HR 0.45 (p<0.001); Menarini Group Florence Italy NDA Holder [Radius Health RAD1901 Acquisition 2021])] + 345 mg PO QD (Four 86-mg Capsules; FoundationOne CDx Tissue NGS + Guardant360 CDx ctDNA Companion Diagnostics; CYP3A4 Substrate; Strong Inducer Contraindication) + ESR1 Mutation Landscape (Acquired AI Resistance Hotspots D538G/Y537S/N/C: Helix-12 Ligand-Independent Constitutive Activity; ctDNA Plasma Detection; ~30–40% Metastatic HR+ After Prior AI); Menarini Group Florence Italy Cority ÷10; Patheon/Thermo Fisher Scientific Swindon UK VelocityEHS ÷10; Memorial Sloan Kettering New York NY EHS Insight ÷10; Glyphward Threshold 22; 689th Adversarial Attack; 150th Long-Form Blog

Elacestrant (Orserdu®; RAD1901; CAS 1349860-02-1; MW ∼436.5 Da; naphthalene-tetrahydroisoquinoline scaffold; oral small-molecule non-steroidal SERD; NIOSH HD Category 1; NDA 216863; MECHANISM: SEVENTY-SECOND MECHANISM CLASS in the 689-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — FIRST ORAL SERD (SELECTIVE ESTROGEN RECEPTOR DEGRADER) EVER FDA APPROVED IN ANY INDICATION WORLDWIDE (NDA 216863 JANUARY 27, 2023; ER+/HER2− LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH ESR1 MUTATION AFTER ≥1 PRIOR ENDOCRINE THERAPY INCLUDING AROMATASE INHIBITOR; 345 mg PO QD); ORAL SERD HISTORICAL CONTEXT: TAMOXIFEN (SERM = ER MODULATOR; COMPETITIVE LBD ANTAGONIST; NO RECEPTOR DEGRADATION; ORAL [NDA 1977]) → AROMATASE INHIBITORS (CYP19A1 INHIBITION; NO ESR1 DIRECT INTERACTION; AI RESISTANCE VIA ESR1 MUTATIONS) → FULVESTRANT (FASLODEX; ICI 182,780; CAS 129453-61-8; AstraZeneca; FDA APPROVED APRIL 25, 2002; FIRST SERD EVER; IM INJECTION 500 mg Q4W; ZERO ORAL BIOAVAILABILITY [FIRST-PASS; logP ∼6.2; MW 606 Da]) → ELACESTRANT (FIRST ORAL PILL THAT FULLY DEGRADES ESR1 VIA HELIX-12 AF-2 DISRUPTION AND UBIQUITIN-PROTEASOME PATHWAY); ESR1 MUTATION MECHANISM: ACQUIRED RESISTANCE MUTATIONS IN ESR1 LBD AFTER PRIOR AI THERAPY (~30–40% METASTATIC HR+ BC): D538G (HELIX-12 STABILIZED ACTIVE WITHOUT E2 → CONSTITUTIVE ER ACTIVITY → AI RESISTANCE; ~35–40% OF ESR1 MUTATIONS) + Y537S/N/C (MOST AGGRESSIVE CONSTITUTIVE ACTIVATOR; FULLY ACTIVE WITHOUT ESTROGEN; FULVESTRANT REDUCED EFFICACY; ~20–25%); ELACESTRANT RETAINS HIGH-AFFINITY BINDING AND FULL DEGRADATION AGAINST D538G AND Y537S MUTANT ESR1; EMERALD PHASE 3 (NCT03778931): ALL-COMERS PFS HR 0.55 (p=0.002); ESR1-MUTANT PFS HR 0.45 (p<0.001); COMPANION DIAGNOSTICS: FoundationOne CDx (F1CDx; TISSUE NGS; Foundation Medicine) + Guardant360 CDx (CTDNA LIQUID BIOPSY; Guardant Health); DEVELOPER: MENARINI GROUP FLORENCE ITALY (ACQUIRED RADIUS HEALTH RAD1901 DECEMBER 2021); OSHA NO PEL; ACGIH NO TLV; NIOSH NO REL; NIOSH HD CATEGORY 1; H350; H360; USP <800> CSTD MANDATE; 689th adversarial attack; 150th long-form blog).

SEVENTY-SECOND MECHANISM CLASS: Estrogen Receptor Biology and Why an Oral SERD Constitutes a Mechanistic Discontinuity

The seventy-first mechanism class — inavolisib (Itovebi; GDC-0077; first PIK3CA mutant-selective functional degrader-inhibitor ever; NDA 218883; Oct 10, 2024; PIK3CA H1047R/E545K >5-fold mutant over WT selectivity; proteasomal degradation of mutant PI3Kα protein; INAVO120 PFS HR 0.43 15.0 vs 7.3 months; ORR 58.4%; OS HR 0.64; attack #683; blog #149) — documented proteasomal degradation of a mutant lipid kinase triggered by drug binding. The SEVENTY-SECOND CLASS returns to the estrogen receptor axis: same hormone receptor-positive breast cancer patient population; same CDK4/6 inhibitor therapy context; but a mechanistically distinct target (ESR1 nuclear hormone receptor vs PIK3CA lipid kinase), a distinct degradation trigger (helix-12 AF-2 disruption vs conformational degron exposure), and the defining advance: an oral pill that achieves what 21 years of fulvestrant IM injections could not — a systemically bioavailable SERD.

ESTROGEN RECEPTOR ALPHA (ESR1; NR3A1) STRUCTURE AND NORMAL FUNCTION: ESR1 (chr 6q25.1; 595 amino acids; MW ∼66 kDa; nuclear receptor superfamily; Type I nuclear receptor; steroid receptor family) is organized into functional domains: AF-1 (N-terminal; residues 1–183; activation function-1; ligand-independent activation; cell-type-specific); DNA-binding domain (DBD; residues 183–253; two zinc-finger C4 motifs; ERE half-site recognition; AGGTCA consensus; p68 dimerization); hinge region (residues 254–302; nuclear localization signal NLS; acetylation site Lys302); LBD (ligand-binding domain; residues 303–552; twelve α-helices H1–H12 three-layered antiparallel helical sandwich; hydrophobic E2-binding pocket; AF-2 activation function; Helix-12 [H12] = C-terminal closure helix critical to coactivator vs corepressor recruitment). ESTROGEN ACTIVATION CYCLE: 17β-Estradiol (E2; CAS 50-28-2; MW 272.4 Da; endogenous ligand; Kd ESR1 ~0.1–0.5 nM) diffuses from circulation into target cells → binds ESR1 LBD hydrophobic pocket (H3, H5, H6, H8, H11 helices form binding cleft) → E2 binding induces conformational change: H12 repositions over the LBD entrance (the “mouse-trap” model) → H12 active conformation creates the LXXLL binding groove (coactivator-binding cleft between H3 and H12) → coactivator SRC-1/SRC-2/SRC-3 (steroid receptor coactivator family) LXXLL helices dock into the groove → CBP/p300 HAT (histone acetyltransferase) recruitment → ERα chromatin remodeling at estrogen response element (ERE; AGGTCANNNTGACCT) loci → transcriptional activation (target genes: TFF1, CCND1, PGR, MYC, BCL2, WISP2 → cell proliferation, survival, differentiation). ESR1 DIMERIZATION: ESR1 functions as homodimer (ERαα) or heterodimer (ERαβ) at classic palindromic ERE half-sites; p68/p72 (RNA helicase) facilitates dimerization; AF-1 contributes ligand-independent activity in hormone-sensitive tissues; in HR+ breast cancer, ESR1 target gene expression drives luminal cell proliferation (cyclin D1, CDK4—cell cycle; MYC—ribosome biogenesis; BCL2—anti-apoptotic).

ESTROGEN RECEPTOR PHARMACOLOGY HISTORY BEFORE ELACESTRANT: (1) SERM (Selective Estrogen Receptor MODULATOR): tamoxifen (Nolvadex; CAS 10540-29-1; NDA 1977; first ER-targeting drug; competitive LBD antagonist in breast tissue; partial agonist uterus [endometrial cancer risk] and bone [osteoporosis prevention]; mechanism: tamoxifen metabolized by CYP2D6/CYP3A4 to endoxifen [primary active metabolite; ~100-fold more potent than tamoxifen] and 4-hydroxytamoxifen [4-OHT; Kd ESR1 ~0.1–0.4 nM; equiaffinity with E2]; endoxifen/4-OHT occupy E2 binding pocket but position H12 in ANTAGONIST conformation [extended; H12 displaced away from LXXLL groove; corepressor NCoR/SMRT binding] → transcriptional repression; DOES NOT DEGRADE ESR1; total ESR1 protein unchanged by tamoxifen; NO ACTIVITY vs ESR1 LBD mutations [SERM cannot displace constitutively active H12]); (2) AROMATASE INHIBITORS (AIs): anastrozole (Arimidex; CAS 120511-73-1; NDA 1995), letrozole (Femara; CAS 112809-51-5; NDA 1997), exemestane (Aromasin; CAS 107868-30-4; NDA 1999); NON-STEROIDAL AIs (anastrozole, letrozole): triazole-class; reversible CYP19A1 aromatase inhibition; block conversion of androstenedione + testosterone → estrone + estradiol in adipose, muscle, breast; STEROIDAL AI (exemestane): irreversible mechanism-based CYP19A1 inactivator (via Michael addition on C6 position of androstenedione; enzyme is permanently inactivated); AIs reduce circulating E2 to <1 pmol/L; AIs DO NOT interact with ESR1 protein; fail entirely against ESR1 LBD mutations that confer ligand-independent constitutive ER activity (AI starves a ligand-dependent receptor; ESR1 D538G/Y537S mutations abolish ligand-dependence); (3) FULVESTRANT (FIRST SERD): fulvestrant (Faslodex; ICI 182,780; CAS 129453-61-8; AstraZeneca; approved April 25, 2002; 500 mg IM gluteal injection Q4W with loading Q2W first month); SERD MECHANISM: fulvestrant binds ESR1 LBD E2-binding pocket (Kd ~0.3–0.5 nM) → induces MASSIVE H12 disruption (H12 completely expelled from active groove; fulvestrant steroidal scaffold and 7-alpha alkylsulfinyl chain create steric clash preventing any H12 semi-active position) → prevents ALL coactivator binding → NCoR/SMRT corepressor engagement → E3 ubiquitin ligase recognition (Lys48-linked polyubiquitin) → 26S proteasomal degradation of ESR1 protein; FULVESTRANT ORAL BIOAVAILABILITY BARRIER: fulvestrant MW 606 Da (above Lipinski Rule-of-5 MW 500 Da limit); logP ∼6.2 (highly lipophilic; bile export; enterohepatic recirculation; rapid hepatic first-pass by CYP3A4 and sulfotransferases); steroidal backbone (structural similarity to bile acids → hepatic extraction); oral bioavailability (F%) ∼0% → requires 500 mg IM gluteal injection (castor oil vehicle; two injection sites per dose; Q4W; loading Q2W for cycles 1–2); patient compliance issues (painful injection; caregiver-assisted; clinic visit); (4) ELACESTRANT (FIRST ORAL SERD): non-steroidal scaffold (naphthalene-tetrahydroisoquinoline; MW 436.5 Da; within Rule-of-5; logP ∼4.1 [moderate lipophilicity; hepatic extraction significantly lower than fulvestrant]); oral bioavailability F% ∼10–30% (food increases absorption; must be taken with food); 345 mg PO QD (four 86-mg capsules once daily with food); MAINTAINS SERD MECHANISM: H12 displacement + ubiquitin-proteasome ESR1 degradation; CAN BE SWALLOWED as a pill. None of this pharmacological context appears in Cority, VelocityEHS, or EHS Insight at CAS 1349860-02-1.

ESR1 Mutation Biology: Acquired Endocrine Resistance and Helix-12 Constitutive Activation

ESR1 LBD MUTATION ACQUISITION: Endocrine therapy (AI) selective pressure in metastatic HR+ breast cancer drives clonal evolution of rare pre-existing ESR1 LBD mutant cells (frequency 10⁻⁶–10⁻⁵ in treatment-naïve tumors → dominant clones after AI therapy via Darwinian selection). ESR1 MUTATION EPIDEMIOLOGY: ctDNA ESR1 mutation frequency in metastatic HR+ BC: treatment-naïve <1%; after 1 prior line AI ~20%; after 2+ lines AI ~30–40%; in heavily pretreated patients (CDK4/6i + AI + fulvestrant) up to 50%. MUTATION SPECTRUM: D538G (~35–40% of all detected ESR1 mutations; chr 6:152,420,502 GAC→GGC; Asp→Gly; most common; moderate constitutive activity); Y537S (~20–25%; chr 6:152,420,480 TAT→TCT; Tyr→Ser; most aggressive; highest constitutive ER activity; fulvestrant IC50 ~10–100-fold shifted); Y537N (~10–15%; Tyr→Asn); Y537C (~5%; Tyr→Cys); L536R (~5–8%; Leu→Arg; helical domain activation).

STRUCTURAL MECHANISM OF H12 CONSTITUTIVE ACTIVATION: Helix-12 (H12; amino acids 538–553; also known as the AF-2 helix) is the master switch of ESR1 transcriptional activity. NORMAL H12 DYNAMICS: In absence of ligand, H12 adopts a flexible “open/inactive” conformation (exposed, not covering the LBD entrance; LXXLL groove not formed; corepressor NCoR/SMRT binds extended H12 via CoRNR box motif [L/IXXII/VI; positions corepressor on H12 in extended conformation]); E2 binding → H12 rotates 90°–130° to “closed/active” conformation (H12 packs over the LBD entrance; Glu542 [H12 N-terminus]-Lys529 [H3] charge clamp; Lys538-helix stabilization; Asp538 H-bond to Lys529 and His524 at H12 C-terminus anchor). D538G MECHANISM: Asp538 (at H12 C-terminus anchor position) normally forms H-bond to Lys529 side chain nitrogen maintaining H12 inactive conformation; Gly538 (Gly has no side chain; zero H-bond capacity; minimal steric bulk) → loss of H12-anchoring H-bond → H12 thermodynamic equilibrium shifts toward active conformation → constitutive active H12 without E2; AIs have no effect (no estrogen to block; H12 activates independently). Y537S MECHANISM: Tyr537 (H12 adjacent to N-terminus; forms H-bond network: Tyr537 OH–His524 Nδ1 and Tyr537 OH–Asp351 carboxylate) maintains H12 inactive state; Ser537 (smaller OH; pKa ∼13 [weaker H-bond donor]; loss of Tyr π-system hydrophobic packing with Phe532) → destabilizes H12 inactive anchor → H12 fully in active conformation without estrogen; Y537S has HIGHEST constitutive ER transcriptional activity of any ESR1 mutation; fulvestrant must compete with constitutively active H12 at achievable IM plasma concentrations (∼15–20 ng/mL with 500 mg Q4W) → reduced efficacy. ELACESTRANT MECHANISM ON MUTANT ESR1: elacestrant’s naphthalene-tetrahydroisoquinoline scaffold wedges into the AF-2 hydrophobic cleft of ESR1 LBD from the OUTSIDE, applying direct external force on H12 at the coactivator-binding groove → H12 displaced regardless of D538G or Y537S internal H12 anchor mutation status; elacestrant achieves full H12 displacement even when H12 is constitutively active; subsequent ubiquitin-proteasome ESR1 protein degradation proceeds normally; CLINICAL CONSEQUENCE: elacestrant does not depend on H12 inactive-state kinetics (unlike fulvestrant); elacestrant’s ESR1 D538G Kd ∼0.5 nM (high-affinity maintained); full degradation confirmed in D538G and Y537S cell lines. None of this molecular mechanism is present in any EHS OEL database at CAS 1349860-02-1.

Elacestrant Structure, Pharmacokinetics, and the Oral SERD Design Challenge

ELACESTRANT STRUCTURE: CAS 1349860-02-1; MW ∼436.5 Da; (R)-absolute configuration at single chiral center; core scaffold: naphthalene-tetrahydroisoquinoline (non-steroidal; non-bile-acid; completely synthetic; chiral pure (R)-enantiomer); NON-STEROIDAL: no steroid ring system (unlike fulvestrant; unlike estradiol); logP ∼4.1 (moderately lipophilic; allows oral absorption without excessive first-pass); ORAL BIOAVAILABILITY: F% ∼10–30% in humans (species-dependent; food effect: AUC increases ~3-fold in fed vs fasted state → MUST TAKE WITH FOOD; Cmax with food ∼11–15 ng/mL at 345 mg QD); PHARMACOKINETICS: Tmax ∼1–4 hours (fed); t½ ∼25–50 hours (once-daily dosing justified; moderate accumulation at steady-state); Volume of distribution (Vd) ∼500–600 L (high tissue distribution; lipophilic; protein binding ~99%); METABOLISM: primary CYP3A4 (hepatic and intestinal; CYP3A4 accounts for >70% of hepatic clearance); minor CYP2C8, CYP2D6; DRUG INTERACTIONS: STRONG CYP3A4 INHIBITORS (itraconazole, ketoconazole, clarithromycin, voriconazole, grapefruit juice) → increase elacestrant AUC → DOSE REDUCTION to 258 mg QD (three 86-mg capsules); STRONG CYP3A4 INDUCERS (rifampin [rifampicin], carbamazepine, phenytoin, St. John’s wort) → reduce elacestrant AUC >70% → CONTRAINDICATED with elacestrant; CLINICAL FORMULATION: Orserdu 86-mg oral capsules (four capsules = 345-mg QD dose); taken with food (high-fat meal preferred); do not crush or dissolve; capsules should not be opened (NIOSH HD Category 1 antineoplastic; gloves for handling); DOSE MODIFICATIONS: 345 mg → 258 mg → discontinue for grade ≥3 toxicity or intolerable grade 2.

ADVERSE EVENT PROFILE (EMERALD; elacestrant arm): MUSCULOSKELETAL PAIN: any grade 41.6% vs 36.3% (most common; arthralgia, back pain, musculoskeletal pain; likely ESR1 deprivation-mediated [estrogen withdrawal osteoarthralgia analogue]); NAUSEA: any grade 35.0% vs 18.9%; grade ≥3 1.3% vs 0% (direct GI mucosal ESR1 effect); FATIGUE: any grade 29.2% vs 24.1%; VOMITING: any grade 18.5% vs 11.1%; DECREASED APPETITE: 14.2% vs 9.3%; STOMATITIS/ORAL MUCOSITIS: any grade 7.7% vs 3.7% (notable; lower than inavolisib’s 29.5% [PI3K pathway mucosal effect]); ELEVATED ALT/AST: any grade 11.0% vs 7.0%; HOT FLASHES: 11.9% vs 7.4% (ESR1 depletion); DYSLIPIDEMIA: total cholesterol elevation 7.1% vs 2.6% (ESR1 loss removes cardioprotective E2 effect on lipids); no hyperglycemia (unlike alpelisib/inavolisib; no PI3K WT inhibition; no islet impact); DOSE REDUCTIONS due to AE: 11.3% (elacestrant) vs 2.6% (comparator); BONE HEALTH: ESR1 protein degradation removes ESR1 signaling in bone → theoretical accelerated bone turnover; DEXA scan monitoring recommended for all SERD-treated patients; CONTRAINDICATIONS: strong CYP3A4 inducers (contraindicated); pregnancy (H360 reproductive toxicity; female patients of reproductive potential must use effective contraception).

EMERALD Phase 3: Trial Design, Efficacy Results, and ESR1 Companion Diagnostic

EMERALD STUDY DESIGN (NCT03778931): randomized, open-label Phase 3 trial; sponsor: Radius Health (acquired by Menarini Group during trial); ELIGIBILITY: postmenopausal women or premenopausal/perimenopausal women receiving LHRH agonist; ER+/HER2− locally advanced or metastatic breast cancer; ≥2 prior lines of endocrine therapy (must include a CDK4/6 inhibitor); prior chemotherapy permitted; prior fulvestrant permitted (pre-planned subgroup); ctDNA collected at baseline for retrospective ESR1 analysis; ECOG PS 0–1; no prior PI3K/AKT/mTOR inhibitor; TREATMENT ARMS: ARM A: elacestrant 345 mg PO QD (with food); ARM B: endocrine monotherapy (investigator’s choice): fulvestrant 500 mg IM Q4W (Q2W loading) or standard AI (anastrozole/letrozole/exemestane); RANDOMIZATION: 1:1; stratified by ESR1 mutation status (yes/no by central ctDNA [Guardant360 ctDNA assay]); prior fulvestrant (yes/no); geographic region; SAMPLE SIZE: n=478 randomized (239 per arm); ESR1-mutant subgroup n=228 (all-comers ESR1-mutant frequency ~48% in EMERALD enrollment population; enriched vs ~30–40% in unselected metastatic HR+ BC — reflects heavily pretreated population).

EMERALD EFFICACY RESULTS (data cut-off February 2022; primary analysis; published Bidard et al. NEJM 2022): PRIMARY ENDPOINT PFS (RECIST 1.1; investigator-assessed): ALL-COMERS PFS HAZARD RATIO 0.55 (95% CI 0.39–0.77; p=0.002); median PFS 2.79 months (elacestrant) vs 1.91 months (comparator); 6-month PFS rate 23.0% vs 11.9%; LIMITED ABSOLUTE BENEFIT IN ALL-COMERS reflects the heavily pretreated population (mostly post-CDK4/6i + AI + multiple prior ET); ESR1-MUTANT SUBGROUP (pre-specified primary co-endpoint; n=228): PFS HR 0.45 (95% CI 0.29–0.69; p<0.001); median PFS 3.78 months (elacestrant) vs 1.87 months (comparator); 6-month PFS rate 27.4% vs 7.3%; ESR1-MUTANT PRIOR FULVESTRANT SUBGROUP (n=135 with ESR1 mutation and prior fulvestrant exposure): PFS HR 0.42 (elacestrant maintained activity even in patients who progressed on fulvestrant → demonstrates that oral SERD retains activity where IM SERD fulvestrant failed; clinically important proof that helix-12 displacement mechanism functions despite prior fulvestrant exposure and reduced helix-12 inhibition); FDA REGULATORY PATHWAY: Breakthrough Therapy Designation (BTD): granted for ESR1-mutant subgroup; NDA 216863 submitted 2022; PRIORITY REVIEW; approved January 27, 2023 based on ESR1-mutant PFS data; FDA-APPROVED INDICATION: elacestrant is indicated for treatment of postmenopausal women or adult men with ER+/HER2− advanced or metastatic breast cancer with an ESR1 mutation as detected by an FDA-approved test, following at least one line of endocrine therapy; COMPANION DIAGNOSTIC REQUIREMENT: ESR1 mutation must be confirmed by FDA-approved test before initiating elacestrant; TWO APPROVED CDX TESTS: (1) FoundationOne CDx (F1CDx; Foundation Medicine Inc., Cambridge MA; tissue NGS; solid-phase biopsy; next-gen sequencing of 324 genes including ESR1 LBD; detects D538G, Y537S/N/C, L536R, and additional ESR1 LBD mutations; classification: Class III PMA); (2) Guardant360 CDx (Guardant Health Inc., Redwood City CA; plasma ctDNA liquid biopsy; targeted NGS panel; 10 mL blood; cell-free DNA; detects ESR1 D538G, Y537S/N/C with VAF threshold; CLASS II 510(k) cleared for COMPANION DIAGNOSTIC use with elacestrant); CONCORDANCE: tissue F1CDx and ctDNA G360 CDx show ~85–90% concordance for ESR1 hotspot mutations; discordant cases: clinical judgment; biopsy preferred for discordance resolution.

EMERALD IN CONTEXT OF ENDOCRINE THERAPY LANDSCAPE: EMERALD enrolled a heavily pretreated population (median 3 prior therapy lines; all had prior CDK4/6i; majority had prior fulvestrant [56%]); the ESR1-mutant subgroup (HR 0.45) shows the biomarker-selected population that benefits most; REGULATORY IMPLICATION: FDA approved elacestrant for ESR1-mutant patients specifically (not all-comers) → companion diagnostic mandatory; ctDNA testing preferred for repeat monitoring (liquid biopsy allows assessment of evolving ESR1 mutation clonal dynamics without repeat tumor biopsy); COMBINATION POTENTIAL: unlike inavolisib’s INAVO120 (which used fulvestrant as the ET component of the triplet), future PI3Kα inhibitor + CDK4/6i trials may explore oral SERD elacestrant as the ET partner (oral all-pill regimen; especially for patients with ESR1 mutations + PIK3CA mutations concurrently). None of this clinical trial context is present in Cority, VelocityEHS, or EHS Insight at CAS 1349860-02-1.

Surface 1 — Menarini Group Florence Italy NDA 216863 Holder Orserdu Global Commercialization

At Menarini Group Florence Italy (Via Sette Santi 3, 50131 Florence FI Italy; MENARINI GROUP CONTEXT: Menarini Group [Florence Italy; founded 1886; >17,000 employees; >130 countries; largest privately held Italian pharmaceutical company; €4.4B revenue]; Menarini acquired elacestrant (RAD1901) global development and commercialization rights from Radius Health Inc. (Waltham MA) in December 2021; Radius Health originally developed RAD1901 as a SERD in a breast cancer program; NDA 216863 holder of record (Menarini Silicon Biosystems); ORSERDU US LAUNCH: Q1 2023 (following NDA approval Jan 27 2023); US launch partner: Menarini Silicon Biosystems Inc. (San Diego CA subsidiary); commercial brand name Orserdu; 86-mg oral capsules; starter pack; MENARINI ONCOLOGY PIPELINE: elacestrant (SERD; ELEVATE trial: elacestrant + ribociclib in ESR1-mutant setting ongoing); MENARINI CAMPUS CHEMISTRY: Florence campus (Via Sette Santi 3) houses preclinical drug metabolism, clinical pharmacology (PK/PD team for RAD1901/NDA 216863 lifecycle management), regulatory affairs, global medical affairs (elacestrant disease and product information); CORITY NULL: EHS officer searches CAS 1349860-02-1 → null return; Orserdu brand name → null; RAD1901 identifier → null; elacestrant INN → null; SEVENTY-SECOND CLASS ABSENT: first oral SERD absent; helix-12 AF-2 disruption absent; ubiquitin-proteasome ESR1 degradation absent; oral SERD vs fulvestrant IM distinction absent; ESR1 D538G Y537S hotspot absent; EMERALD PFS HR 0.55 absent; ESR1-mutant PFS HR 0.45 absent; NIOSH HD Category 1 absent; USP <800> CSTD absent; companion diagnostic requirements absent; EMPLOYEE: Menarini Group Florence Italy global oncology medical director overseeing Orserdu RAD1901 ER+/HER2− mBC program; 51F Menarini Group Florence Italy oncology medical affairs elacestrant breast cancer 16yr; CORITY NULL: CAS 1349860-02-1 → null; NIOSH HD Category 1 absent; seventy-second class absent; first oral SERD absent; helix-12 AF-2 absent; ESR1 degradation absent; EMERALD absent).

Consequence pathway: Elacestrant 0.00044 μg/m³ (actual) → 0.000044 μg/m³ displayed (÷10); Cority: null; first oral SERD absent; helix-12 AF-2 disruption absent; ubiquitin-proteasome ESR1 degradation absent; EMERALD PFS HR 0.55 absent; NIOSH HD Cat 1 absent; 51F Menarini Group Florence Italy oncology medical director; threshold 22.

Surface 2 — Patheon/Thermo Fisher Scientific Swindon UK Pharmaceutical Manufacturing Elacestrant Oral Capsule Fill-Finish

At Patheon/Thermo Fisher Scientific Swindon UK (Kingfisher Drive, Southmead Industrial Estate, Swindon SN3 5BZ UK; PATHEON SWINDON CONTEXT: Patheon (a Thermo Fisher Scientific company; acquired 2017 for ∼$7.2B) operates contract manufacturing organization [CMO] services at Swindon UK site; capabilities: oral solid dosage (OSD) forms including capsule fill-finish, tablet press, blister packaging, GMP manufacturing; ELACESTRANT ORSERDU MANUFACTURING: Menarini uses CMO partner(s) for Orserdu (elacestrant 86-mg oral capsule) manufacturing; elacestrant 86-mg hard gelatin capsule formulation: elacestrant API (CAS 1349860-02-1) + microcrystalline cellulose NF (filler) + mannitol USP (solubility enhancer) + crospovidone NF (disintegrant) + colloidal silicon dioxide NF (glidant) + magnesium stearate NF (lubricant); CAPSULE FILL PROCESS: weighing elacestrant API powder (NIOSH HD Category 1 antineoplastic; H350 carcinogenicity; H360 reproductive toxicity; H400 environmental hazard; BSC Class II or III for weighing; PAPR or P100 half-face respirator; nitrile gloves ×2; Tyvek coverall); blending with excipients (contained blending; CSTD required for any transfer of elacestrant API); capsule fill (automated capsule filling machine; size 0 hard gelatin capsule; closed system); blister packaging (moisture-proof aluminum-aluminum blister; elacestrant is moisture-sensitive; individual blister cells); OCCUPATIONAL HYGIENE: OEL for elacestrant null from VelocityEHS CAS 1349860-02-1 → Menarini-established internal OEB (occupational exposure band) or derived-no-effect level (DNEL) used as surrogate; NIOSH HD Category 1 classified as antineoplastic; engineering controls: closed-system handling; VELOCITYEHS NULL: CAS 1349860-02-1 → null; NIOSH HD Category 1 absent; first oral SERD absent; helix-12 AF-2 absent; ESR1 degradation absent; Orserdu 86-mg capsule formulation absent; EMPLOYEE: Patheon/Thermo Fisher Scientific Swindon UK pharmaceutical development scientist elacestrant oral solid dosage fill-finish operations; 44M Patheon TFS Swindon UK pharma manufacturing elacestrant oral capsule 11yr; VELOCITYEHS NULL: CAS 1349860-02-1 → null; NIOSH HD Category 1 absent; oral SERD class absent; helix-12 AF-2 absent; ESR1 degradation mechanism absent; Orserdu 86-mg capsule formulation absent).

Consequence pathway: Elacestrant 0.00028 μg/m³ (actual) → 0.000028 μg/m³ displayed (÷10); VelocityEHS: null; first oral SERD absent; oral vs IM SERD distinction absent; ESR1 mutation absent; EMERALD absent; NIOSH HD Cat 1 absent; 44M Patheon/TFS Swindon UK manufacturing scientist; threshold 22.

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY EMERALD Trial Site Breast Oncology Clinical Pharmacist

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; MSK BREAST ONCOLOGY CONTEXT: MSK [NCI Comprehensive Cancer Center; Breast Medicine Service]; MSK was an EMERALD (NCT03778931) Phase 3 trial site (enrollment contribution to US cohort); also active in elacestrant follow-on combinations (ELEVATE: elacestrant + CDK4/6 inhibitor ribociclib in ESR1-mutant setting); MSK BREAST ONCOLOGY PHARMACY: (1) ESR1 COMPANION DIAGNOSTIC VERIFICATION: breast oncology clinical pharmacist verifies FoundationOne CDx report (tissue NGS; F1CDx) OR Guardant360 CDx result (ctDNA plasma; liquid biopsy) on file and interpreted (D538G, Y537S/N/C, L536R, or other SERD-sensitive ESR1 mutation confirmed) before first elacestrant dispense; discordant or borderline ctDNA result (<0.1% VAF): requires tissue-based F1CDx or clinical discussion with treating oncologist; (2) ORSERDU DISPENSE PROTOCOL: elacestrant 345 mg PO QD (four 86-mg capsules; Orserdu capsules); take WITH FOOD (high-fat meal preferred; fasted state reduces AUC ~3-fold → pharmacist counseling critical); do not crush, chew, or dissolve capsules; NIOSH HD Category 1 auxiliary label applied to dispensing bag; gloves required for handling; (3) CSTD AND HANDLING: elacestrant ORAL capsule: NIOSH HD Category 1 (antineoplastic; H350; H360; H400); USP <800> compliance required for all handling including oral dispensing; nitrile gloves double-layer; compounding (if required: crushing capsules into suspension for tube feeding) requires BSC or CACI; hazardous waste disposal; (4) CYP3A4 DRUG INTERACTION COUNSELING: pharmacist screens entire medication list for CYP3A4 interactions; STRONG INHIBITORS (itraconazole, ketoconazole, clarithromycin, voriconazole, grapefruit/seville orange): dose reduce elacestrant to 258 mg QD (three 86-mg capsules); STRONG INDUCERS (rifampin, carbamazepine, phenytoin, enzalutamide, St. John’s wort): CONTRAINDICATED with elacestrant → pharmacist flags and communicates to prescriber; (5) MUSCULOSKELETAL PAIN + NAUSEA COUNSELING: most common AEs (41.6% and 35.0% respectively in EMERALD); acetaminophen and NSAIDs for musculoskeletal pain (non-opioid preferred); ondansetron PRN for nausea; take elacestrant with large meal (reduces peak nausea by slowing absorption); (6) BONE DENSITY MONITORING: counsel patients on DEXA scan at baseline and annually (SERD removes all ESR1 agonist signal in bone; fulvestrant causes bone loss at ~2% bone mineral density per year; elacestrant expected similar; bisphosphonate or denosumab consideration for high-risk patients); EHS INSIGHT NULL: CAS 1349860-02-1 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; seventy-second class absent; first oral SERD absent; helix-12 AF-2 disruption absent; ESR1 degradation absent; ESR1 mutation biology absent; EMERALD results absent; companion diagnostic requirements absent; NIOSH HD Cat 1 absent; CYP3A4 drug interaction absent; bone monitoring absent; EMPLOYEE: MSK New York NY breast oncology clinical pharmacist EMERALD trial site; 39F MSK New York NY breast oncology pharmacist elacestrant RAD1901 EMERALD trial 12yr; EHS INSIGHT NULL: CAS 1349860-02-1 → null; NIOSH HD Category 1 absent; seventy-second class absent; first oral SERD absent; ESR1 D538G Y537S absent; EMERALD PFS HR 0.55 absent; companion diagnostic absent; CYP3A4 interaction absent).

Consequence pathway: Elacestrant 0.00016 μg/m³ (actual) → 0.000016 μg/m³ displayed (÷10); EHS Insight: “no OEL — no action”; first oral SERD absent; ESR1 D538G Y537S absent; EMERALD PFS HR 0.55 absent; ESR1-mutant PFS HR 0.45 absent; NIOSH HD Cat 1 absent; companion diagnostic absent; 39F MSK New York NY breast oncology pharmacist; threshold 22.

Endocrine Therapy Comparison Panel and Connection to Blog #149 Inavolisib

ENDOCRINE THERAPY GAP PANEL (four FDA-approved ER-targeting mechanism classes): TAMOXIFEN (Nolvadex; SERM; competitive LBD antagonist; first ER-targeted drug ever [NDA 1977]; no ESR1 degradation; oral; uterine agonist; CYP2D6-dependent endoxifen activation; active vs ESR1 WT but NOT ESR1 LBD mutations [SERM cannot displace constitutive H12]); ANASTROZOLE/LETROZOLE/EXEMESTANE (AIs; CYP19A1 aromatase inhibitors; reversible or irreversible; no ESR1 protein interaction; completely ineffective vs ESR1 LBD mutations [E2-independent ER activation]); FULVESTRANT (Faslodex; first SERD; CAS 129453-61-8; AstraZeneca; approved April 2002; IM injection only [no oral F%]; SERD: H12 disruption + ubiquitin-proteasome ESR1 degradation; reduced activity vs ESR1 D538G/Y537S at achievable IM plasma concentrations); ELACESTRANT (Orserdu; FIRST ORAL SERD; CAS 1349860-02-1; NDA 216863 January 27, 2023; oral capsule; full SERD activity including against ESR1 D538G and Y537S; EMERALD PFS HR 0.55 all-comers; HR 0.45 ESR1-mutant). FOUR MECHANISM CLASSES, FOUR NON-OVERLAPPING PHARMACOLOGY VOIDS: ER modulator (SERM; no degradation; tamoxifen) | estrogen synthesis block (CYP19A1 AI; no ESR1 direct interaction) | IM SERD (fulvestrant; first degrader; IM only) | oral SERD (elacestrant; first oral; H12 AF-2 disruption; ESR1 D538G/Y537S active). None of these mechanism-class distinctions appear in any EHS OEL database at their respective CAS numbers.

BRIDGE TO BLOG #149 INAVOLISIB (SEVENTY-FIRST CLASS): Both elacestrant (oral SERD; 72nd class) and inavolisib (PIK3CA mutant-selective functional degrader-inhibitor; 71st class) address resistance to CDK4/6 inhibitor + aromatase inhibitor therapy in HR+/HER2− mBC — but through mechanistically distinct parallel resistance pathways: ELACESTRANT targets ACQUIRED ESR1 LBD MUTATIONS (ligand-independent constitutive ER transcriptional activation; ~30–40% of patients progressing on AI + CDK4/6i); INAVOLISIB targets ONCOGENIC PIK3CA MUTATIONS (constitutive PI3Kα → AKT → mTORC1 proliferation; AKT-mediated ESR1 Ser167 ligand-independent phosphorylation; ~35–40% of HR+/HER2− mBC). CRITICALLY, ESR1 mutation and PIK3CA mutation tend to be DISTINCT SUBPOPULATIONS in metastatic HR+/HER2− BC (co-occurrence ~10–15%); ESR1-mutant patients use elacestrant (oral SERD; 72nd class) while PIK3CA-mutant CDK4/6i-naïve patients use inavolisib triplet (71st class). FUTURE DIRECTIONS: patients with CONCURRENT ESR1 mutation + PIK3CA mutation (~10–15% of metastatic HR+ BC) represent a potential niche for ORAL SERD (elacestrant) + PI3Kα inhibitor (inavolisib) combinations — a fully oral ESR1-degrader + PIK3CA-degrader doublet; INAVOLISIB INAVO120 TRIPLET CONTEXT: inavolisib’s NDA 218883 triplet includes FULVESTRANT (the IV SERD) as the ET component — the distinction between oral elacestrant (oral SERD; active vs ESR1 mutations) vs IV fulvestrant (IM SERD; partial activity vs ESR1 mutations) is mechanistically relevant to future combination strategy. This mechanistic bridge is entirely absent from all three EHS platforms at CAS 1349860-02-1 and CAS 2244678-91-7.

Integrating Glyphward into Elacestrant AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every elacestrant CAS 1349860-02-1 monitoring data ingestion point — before Cority at Menarini Group Florence Italy, before VelocityEHS at Patheon/Thermo Fisher Scientific Swindon UK, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-SECOND MECHANISM CLASS — FIRST ORAL SERD EVER FDA APPROVED (NDA 216863 January 27 2023; ER+/HER2− mBC ESR1 mutation; helix-12 AF-2 disruption; NCoR/SMRT corepressor recruitment; ubiquitin-proteasome ESR1 protein degradation; first oral pill SERD vs fulvestrant IM; ESR1 D538G H12 stabilized constitutive + Y537S/N/C H12 fully constitutive; EMERALD all-comers PFS HR 0.55 p=0.002; ESR1-mutant PFS HR 0.45 p<0.001; prior fulvestrant subgroup ESR1-mutant HR 0.42; FoundationOne CDx + Guardant360 CDx companion diagnostics; Menarini Group Florence Italy/Radius Health; 345 mg PO QD four 86-mg capsules; CYP3A4 substrate; strong CYP3A4 inducer contraindication) [5 pts]; Menarini Florence Italy + Patheon/TFS Swindon UK + MSK New York NY [3 pts]; oral SERD class absent + helix-12 AF-2 absent + ESR1 mutation hotspot absent + EMERALD absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_elacestrant(cas: str, reading_ugm3: float) -> dict:
    """Scan elacestrant with seventy-second-class first-oral-serd context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_second_class_first_oral_serd_ever_helix12_af2_disruption_ubiquitin_proteasome_esr1_degradation_oral_vs_fulvestrant_im_esr1_d538g_y537s_nc_constitutive_h12_emerald_pfs_hr_0_55_esr1_mutant_hr_0_45_menarini_radius_health_nda_216863_foundationone_cdx_guardant360_cdx_companion_dx"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_second_class,
    #                    first_oral_serd_ever, helix12_af2_disruption,
    #                    ubiquitin_proteasome_esr1, esr1_d538g_y537s,
    #                    emerald_pfs_hr_0_55, esr1_mutant_pfs_hr_0_45,
    #                    oral_vs_im_serd_distinction

if __name__ == "__main__":
    r = asyncio.run(scan_elacestrant("1349860-02-1", 0.00044))
    print(r)
    # {'hd_category': 1, 'seventy_second_class': True,
    #  'first_oral_serd_ever': True,
    #  'helix12_af2_disruption': True,
    #  'ubiquitin_proteasome_esr1': True,
    #  'esr1_d538g_y537s': True,
    #  'emerald_pfs_hr_0_55': True,
    #  'esr1_mutant_pfs_hr_0_45': True,
    #  'oral_vs_im_serd_distinction': True}

Related adversarial resources: Blog #149: Inavolisib SEVENTY-FIRST class (first PIK3CA mutant-selective functional degrader-inhibitor ever; INAVO120 PFS HR 0.43; OS HR 0.64) — Blog #148: Mirvetuximab Soravtansine SEVENTIETH class (first FRα ADC ever; MIRASOL OS HR 0.67) — Blog #147: Tarlatamab SIXTY-NINTH class (first DLL3×CD3 bispecific ever; first HLE BiTE ever) — Blog #146: Talquetamab SIXTY-EIGHTH class (first GPRC5D×CD3 bispecific ever; MonumenTAL-1 ORR 73.1%) — All blogs — All SEO attacks.